Once-daily oral icotrokinra versus placebo and once-daily oral deucravacitinib in participants with moderate-to-severe plaque psoriasis (ICONIC-ADVANCE 1 & 2): two phase 3, randomised, placebo-controlled and active-comparator-controlled trials.

每日一次口服 icotrokinra 對比安慰劑及每日一次口服 deucravacitinib 用於中重度斑塊型乾癬患者（ICONIC-ADVANCE 1 & 2）：兩項第三期、隨機、安慰劑對照及主動對照試驗